Onmel is owned by Sebela Ireland Ltd.
Onmel contains Itraconazole.
Onmel has a total of 1 drug patent out of which 0 drug patents have expired.
Onmel was authorised for market use on 29 April, 2010.
Onmel is available in tablet;oral dosage forms.
Onmel can be used as onychomycosis of the toenail caused by tricophyton rubrum or trichophyton mentagrophytes, once daily use for 12 consecutive weeks.
The generics of Onmel are possible to be released after 03 October, 2028.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8486456||SEBELA IRELAND LTD||Itraconazole compositions with improved bioavailability|| |
(5 years from now)
Market Authorisation Date: 29 April, 2010
Treatment: Onychomycosis of the toenail caused by tricophyton rubrum or trichophyton mentagrophytes, once daily use for 12 consecutive weeks
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic